1 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial (vol 401, pg 105, 2023) [期刊论文]
LANCET,2023年
LicenseType:Free |
预览 | 原文链接 | 全文 [ 浏览:0 下载:0 ]
2 The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein) (vol 401, pg 568, 2023) [期刊论文]